Cargando…

A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma

The combination of Sintilimab with pemetrexed/platinum has become the first-line treatment for non-squamous non-small-cell lung carcinoma (NSCLC). Here, we report a patient with metastatic large cell neuroendocrine carcinoma (LCNEC) treated with Sintilimab for five cycles who developed shortness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Siming, Zhang, Haiyu, Hu, Bingshuang, Zhou, Jiaxiong, Wen, Lei, Li, Minying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277459/ https://www.ncbi.nlm.nih.gov/pubmed/37342584 http://dx.doi.org/10.1016/j.heliyon.2023.e16874

Ejemplares similares

A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy
por: Li, Minying, et al.
Publicado: (2022)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report
por: Wang, Chen, et al.
Publicado: (2023)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic Thymoma: A Case Report
por: Yang, Zi-xuan, et al.
Publicado: (2021)

Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review
por: Liu, Xin, et al.
Publicado: (2023)

Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report
por: Lin, Yunling, et al.
Publicado: (2022)

Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report
por: Zhang, Lin, et al.
Publicado: (2020)

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
por: Tian, Zhichao, et al.
Publicado: (2022)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
por: Li, Yi‐hui, et al.
Publicado: (2021)

Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma
por: Dai, Lei, et al.
Publicado: (2021)

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Zhang, Menglong, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma
por: Shi, Zheng, et al.
Publicado: (2023)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma
por: Zhou, Bo, et al.
Publicado: (2022)

Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma
por: Liang, Zuoyu, et al.
Publicado: (2022)

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature
por: Ma, Shuzhen, et al.
Publicado: (2020)

Equivalent Survival between Gastric Large-Cell Neuroendocrine Carcinoma and Gastric Small-Cell Neuroendocrine Carcinoma
por: Li, Zefeng, et al.
Publicado: (2023)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
por: Zhang, Zhipeng, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature
por: Zhang, Yong, et al.
Publicado: (2021)

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
por: Xing, Qian, et al.
Publicado: (2020)

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation
por: Wang, Kang, et al.
Publicado: (2023)

Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
por: Hao, Yuan-Yuan, et al.
Publicado: (2022)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients
por: He, Yuwen, et al.
Publicado: (2023)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Retracted: Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Markers, Disease
Publicado: (2023)

Cardiac infarction caused by PD-1 inhibitor during small cell neuroendocrine carcinoma of the ureter treatment: A case report
por: Li, Xiaoying, et al.
Publicado: (2023)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)
por: Salido Iniesta, Mario, et al.
Publicado: (2020)

Duodenal large-cell neuroendocrine carcinoma as unusual cause of acute pancreatitis
por: Zenovia, Sebastian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3i66q97laq8i9egvsdduuo2hc